Literature DB >> 9713266

Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI.

O Pagani1, A O'Neill, M Castiglione, R D Gelber, A Goldhirsch, C M Rudenstam, J Lindtner, J Collins, D Crivellari, A Coates, F Cavalli, B Thürlimann, E Simoncini, M Fey, K Price, H J Senn.   

Abstract

Adjuvant chemotherapy-induced amenorrhoea has been shown to be associated with reduced relapses and improved survival for premenopausal breast cancer patients. Amenorrhoea was, therefore, studied to define features of chemotherapy (i.e. duration and timing) and disease-related factors which are associated with its treatment effects. We reviewed data from IBCSG Trial VI, in which accrual was between July 1986 and April 1993. 1196 of the 1475 eligible patients (81%) were evaluable for this analysis. The median follow-up was 60 months. Women who experienced amenorrhoea had a significantly better disease-free survival (DFS) than those who did not (P = 0.0004), although the magnitude of the effect was reduced when adjusted for other prognostic factors (P = 0.09). The largest treatment effect associated with amenorrhoea was seen in patients assigned to receive only three initial CMF courses (5-yr DFS: 67% versus 49%, no amenorrhoea; hazard ratio, 0.55; 95% confidence interval, 0.38 to 0.81; P = 0.002). DFS differences between amenorrhoea categories were larger for patients with ER/PR positive tumours (hazard ratio, 0.65; 95% confidence interval, 0.53 to 0.80; P = 0.0001). Furthermore, patients whose menses returned after brief amenorrhoea had a DFS similar to those whose menses ceased and did not recover (hazard ratio, 1.10; 95% confidence interval, 0.75 to 1.62; P = 0.63). The effects associated with a permanent or temporary chemotherapy-induced amenorrhoea are especially significant for node-positive breast cancer patients who receive a suboptimal duration of CMF chemotherapy. Cessation of menses, even for a limited time period after diagnosis of breast cancer, might be beneficial and should be prospectively investigated, especially in patients with oestrogen receptor-positive primaries.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9713266     DOI: 10.1016/s0959-8049(97)10036-3

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  41 in total

1.  Phase II study of gonadotropin-releasing hormone analog for ovarian function preservation in hematopoietic stem cell transplantation patients.

Authors:  Yee Chung Cheng; Mariko Takagi; Andrea Milbourne; Richard E Champlin; Naoto T Ueno
Journal:  Oncologist       Date:  2012-01-26

Review 2.  Hormonal therapy for primary breast cancer: scientific rationale and status of clinical research.

Authors:  Lisa E Sokolowicz; William J Gradishar
Journal:  Curr Oncol Rep       Date:  2005-01       Impact factor: 5.075

Review 3.  Trends in endocrine therapy and chemotherapy for early breast cancer: a focus on the premenopausal patient.

Authors:  W Jonat; K I Pritchard; R Sainsbury; J G Klijn
Journal:  J Cancer Res Clin Oncol       Date:  2006-01-25       Impact factor: 4.553

4.  Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors.

Authors:  H Irene Su; Mary D Sammel; Luke Velders; Michelle Horn; Corrie Stankiewicz; Jennifer Matro; Clarisa R Gracia; Jamie Green; Angela DeMichele
Journal:  Fertil Steril       Date:  2009-04-18       Impact factor: 7.329

5.  Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor-Positive Early Breast Cancer: Lights and Shadows.

Authors:  Meredith M Regan; Gini F Fleming; Barbara Walley; Prudence A Francis; Olivia Pagani
Journal:  J Clin Oncol       Date:  2019-02-27       Impact factor: 44.544

Review 6.  Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis.

Authors:  Rodrigo R Munhoz; Allan A L Pereira; André D Sasse; Paulo M Hoff; Tiffany A Traina; Clifford A Hudis; Ricardo J Marques
Journal:  JAMA Oncol       Date:  2016-01       Impact factor: 31.777

7.  Adjuvant ovarian suppression in premenopausal breast cancer.

Authors:  Prudence A Francis; Meredith M Regan; Gini F Fleming; István Láng; Eva Ciruelos; Meritxell Bellet; Hervé R Bonnefoi; Miguel A Climent; Gian Antonio Da Prada; Harold J Burstein; Silvana Martino; Nancy E Davidson; Charles E Geyer; Barbara A Walley; Robert Coleman; Pierre Kerbrat; Stefan Buchholz; James N Ingle; Eric P Winer; Manuela Rabaglio-Poretti; Rudolf Maibach; Barbara Ruepp; Anita Giobbie-Hurder; Karen N Price; Marco Colleoni; Giuseppe Viale; Alan S Coates; Aron Goldhirsch; Richard D Gelber
Journal:  N Engl J Med       Date:  2014-12-11       Impact factor: 91.245

Review 8.  Adjuvant Endocrine Therapy in Breast Cancer: Evolving Paradigms in Premenopausal Women.

Authors:  Lorenzo Rossi; Olivia Pagani
Journal:  Curr Treat Options Oncol       Date:  2017-05

9.  Menses resumption after cancer treatment-induced amenorrhea occurs early or not at all.

Authors:  Melanie H Jacobson; Ann C Mertens; Jessica B Spencer; Amita K Manatunga; Penelope P Howards
Journal:  Fertil Steril       Date:  2015-12-01       Impact factor: 7.329

10.  Impact of biomarker changes during neoadjuvant chemotherapy for clinical response in patients with residual breast cancers.

Authors:  Yukie Enomoto; Takashi Morimoto; Arisa Nishimukai; Tomoko Higuchi; Ayako Yanai; Yoshimasa Miyagawa; Keiko Murase; Michiko Imamura; Yuichi Takatsuka; Takashi Nomura; Masashi Takeda; Takahiro Watanabe; Seiichi Hirota; Yasuo Miyoshi
Journal:  Int J Clin Oncol       Date:  2015-09-04       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.